Evidence map›Paper›PMID 27658875›Full record

Observational studyThe lancet. HIV2016

Mortality in HIV-infected women, heterosexual men, and men who have sex with men in Rio de Janeiro, Brazil: an observational cohort study.

Lara Coelho, Beatriz Grinsztejn, Jessica L Castilho, Raquel De Boni, Marcel S B Quintana, Dayse P Campos, Sayonara R Ribeiro, Antonio G Pacheco, Valdilea G Veloso, Paula M Luz

Open access · greenAbstract readObservational Study
In one paragraph

Observational study in The lancet. HIV, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 2 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Lara CoelhoInstituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Beatriz GrinsztejnInstituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Jessica L CastilhoDivision of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, TN, USA.
Raquel De BoniInstituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Marcel S B QuintanaInstituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Dayse P CamposInstituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Sayonara R RibeiroInstituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Antonio G PachecoPrograma de Computação Científica, Fundação Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Valdilea G VelosoInstituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Paula M LuzInstituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz Foundation, Rio de Janeiro, Brazil. Electronic address: paula.luz@ini.fiocruz.br.
Instituto Evandro Chagas · BRFundação Oswaldo Cruz · BRVanderbilt University · US

Funding

CCASAnet: Caribbean, Central and South America NetworkU01AI069923 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Pedro Enrique Cahn, Jessica L Castilho · 2006 to 2026
$41.6M
The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit (FioTrials)UM1AI069476 · NIAID · FUNDACAO OSWALDO CRUZ · PI BEATRIZ GRINSZTEJN · 2012 to 2026
$26.3M
Building Interdisciplinary Research Careers in Women's HealthK12HD043483 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HARTMANN, KATHERINE E, MAJOR, AMY S · 2002 to 2023
$10.3M
NIAID NIH HHS U01 AI069923NIAID NIH HHS UM1 AI069476NICHD NIH HHS K12 HD043483
6 · The paper itself

Abstract

backgroundMortality in HIV-infected individuals might differ by sex and mode of HIV acquisition. We aimed to study mortality in HIV-infected women, heterosexual men, and men who have sex with men (MSM) in a cohort from Rio de Janeiro, Brazil.

methodsIn this observational cohort study, we included HIV-infected women, heterosexual men, and MSM (aged ≥18 years) from the Instituto Nacional de Infectologia Evandro Chagas database who were enrolled between Jan 1, 2000, and Oct 30, 2011, and who had at least 60 days of follow-up. Causes of deaths, defined with the Coding of Death in HIV protocol, were documented. Cox proportional hazards models accounting for competing risks were used to explore risk factors for AIDS-related and non-AIDS-related deaths.

findingsWe had 10 142 person-years of follow-up from 2224 individuals: 817 (37%) women, 554 (25%) heterosexual men, and 853 (38%) MSM. Of 103 deaths occurred, 64 were AIDS related, 31 were non-AIDS related, and eight were of unknown causes. In unadjusted analyses, compared with women, the hazard of AIDS-related deaths was higher for heterosexual men (hazard ratio [HR] 3·52, 95% CI 1·30-9·08; p=0·009) and for MSM (2·30, 0·89-5·94; p=0·084). After adjustment for age, CD4 cell counts, last HIV viral load, antiretroviral therapy use, and AIDS-defining infection, AIDS-defining malignant disease, and hospital admission during follow-up, the excess risk of AIDS-related death decreased for heterosexual men (adjusted HR 1·99, 0·75-5·25; p=0·163) but was unchanged for MSM (2·24, 0·82-6·11; p=0·114). Non-AIDS-related mortality did not differ by group.

interpretationCompared with women, increased risk of AIDS-related death in heterosexual men was partly mitigated by risk factors for AIDS mortality, whereas the excess risk in MSM was unchanged. Further study of reasons for disparity in AIDS-related mortality by mode of transmission is needed.

fundingUS National Institutes of Health, Brazilian National Council of Technological and Scientific Development (CNPq), and Research Funding Agency of the State of Rio de Janeiro (FAPERJ).

Indexed as

Acquired Immunodeficiency SyndromeAdolescentAdultAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveBrazilCD4 Lymphocyte CountCohort StudiesFemaleHeterosexualityHIV InfectionsHomosexuality, MaleHumansMaleProportional Hazards ModelsRisk FactorsAnti-HIV Agents

Identifiers

PMID27658875
PMCPMC5084911
OpenAlexW2513994493

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.